DalCor Pharmaceuticals Completes $150 Million Financing
DalCor Pharmaceuticals today announced the completion of $150 million in private financing to continue development of dalcetrapib in a genetically distinct population of patients with cardiovascular disease.
Roche to Develop Companion Diagnostic Test for Acute Coronary Syndrome
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has entered into an agreement to develop a companion diagnostic (CDx) test for dalcetrapib, a therapeutic from DalCor Pharmaceuticals (DalCor), which will target patients with a specific genotype who have experienced a recent Acute Coronary Syndrome (ACS) event.
DalCor Pharmaceuticals Licenses a Late-Stage Investigational Cardiovascular Drug Following Major Discovery by Montreal Heart Institute (MHI) Scientists
DalCor Pharmaceuticals Canada Inc. (DalCor) and the Montreal Heart Institute (MHI) announced today a collaboration in principle to conduct an international Phase III clinical trial which could result in a major clinical advance in cardiovascular personalised medicine.
